90Y-Besilesomab is the therapeutic analogue of the 99mTc-labeled murine anti-granulocyte mAb BW250/183 available under the trade name Scintimun®. This molecule is developed as a therapeutic agent for the treatment of systemic amyloid light chain amyloidosis (SALA) using the companion diagnostic agent 111In-Besilesomab. 90Y-besilesomab has been granted orphan drug designation status in Europe for the broad indication of Bone Marrow Conditioning (BMC) for Hematopoietic Stem Cell Transplantation (HSCT).
The antibody is targeting CD66 and the 90Y-labeled form is now evaluated in patients affected by amyloidosis on the basis of a SPECT confirmation of the presence of the disease with the 111In-analogue.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.